Episode 819: Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease

This interview is disseminated on behalf of Cardiol Therapeutics Inc.In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.Learn more: https://www.cardiolrx.comWatch the full YouTube interview here: https://youtu.be/NXkzgfWHQnAAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia